NCT04932473Completed
ALFAsleep: Exploring Cognitive and Biological Correlates of Sleep Quality and Their Potential Links With Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 31 May 2025
Brief summary (registry, in English)
The main goal of this study is to perform a multimodal characterization of brain structural and functional changes, as well as changes in Alzheimer's disease (AD) biomarkers, as a function of sleep quality measures. Cross-sectional data will enable us to confirm and expand previous knowledge in a large and well-phenotyped population, while longitudinal data will allow us to test the hypothesis of the existence of a bidirectional relationship between sleep quality and AD.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 179 (actual)
- First submitted
- 8 Jun 2021
- Start date
- 26 Jan 2021
- Primary completion date
- 20 Sept 2022
- Lead sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
- Diseases
- Alzheimer disease
- NCT number
- NCT04932473
What you commit to
- Study type: Observational
- Participants enrolled: 179
- From 26 Jan 2021 to the primary completion date, 20 Sept 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- For the PSG sub-study, participants currently treated with drugs that may interfere in PSG data interpretation (e.g. antidepressants or benzodiazepines).
Other illness
- Presence of cognitive impairment.
- Presence of clinically relevant neurological disorder, psychiatric disorder or other medical conditions that may jeopardize the interpretation of the study results according to the investigator criteria
Who the study is looking for
- Subjects that are currently participating in the ALFA+ study (cognitively healthy adults aged between 45-65 years at the moment of the inclusion in the 45-65/FPM2012 study).
- Subjects from whom CSF and/or neuroimaging biomarkers have been acquired during the last 36 months prior to their enrollment in the current study.
Age in the registry: 45 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Barcelonabeta Brain Research Center Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.